SCHEMBL30656209

SCHEMBL30656209

COC(=O)c1cccc(-c2c(C#N)c(N)nc(N3CCCCC3)c2C#N)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 7/20 0.63
KDM4E B2RXH2 8/20 0.61
HPGD P15428 5/20 0.61
ALDH1A1 P00352 4/20 0.61
RXFP1 Q9HBX9 2/20 0.61
ADRA2A P08913 1/20 0.61
MAPT P10636 5/20 0.54
HSD17B10 Q99714 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
ADORA1 P30542 6/20 0.51
ADORA2B P29275 2/20 0.48
POLB P06746 3/20 0.47
BLM P54132 3/20 0.47
MAPK1 P28482 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
SAE1 Q9UBE0 2/20 0.47
UBA2 Q9UBT2 2/20 0.47
NSD2 O96028 1/20 0.47
GLA P06280 1/20 0.47
ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26632987 1.00 ADORA2A (0.63) ADORA2AKDM4EHPGDALDH1A1RXFP1
SCHEMBL26737977 0.81 ADORA2A (0.61) ADORA2AKDM4EHPGDALDH1A1RXFP1
SCHEMBL7019121 0.80 ADORA1 (0.55) ADORA2AKDM4EHPGDALDH1A1RXFP1
SCHEMBL26632973 0.80 ADORA2A (0.84) ADORA2AKDM4EHPGDALDH1A1RXFP1
SCHEMBL31215447 0.79 ADORA2A (0.71) ADORA2AKDM4EHPGDALDH1A1RXFP1
SCHEMBL26633000 0.79 ADORA2A (0.71) ADORA2AKDM4EHPGDALDH1A1RXFP1
SCHEMBL26633001 0.79 ADORA2A (0.74) ADORA2AKDM4EHPGDALDH1A1RXFP1
SCHEMBL26632965 0.79 ADORA2A (0.70) ADORA2AKDM4EHPGDALDH1A1RXFP1
SCHEMBL26632994 0.79 KDM4E (0.83) ADORA2AKDM4EHPGDALDH1A1RXFP1
SCHEMBL31215444 0.79 ADORA2A (0.69) ADORA2AKDM4EHPGDALDH1A1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4447962-B1 ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER UNIV GENEVE (CH) 2025-08-20 EP disclosed
US-20250115592-A1 ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER UNIVERSITE DE GENEVE (CH) 2025-04-10 US disclosed
EP-4447962-A1 ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER UNIVERSITE DE GENEVE (CH) 2024-10-23 EP disclosed
WO-2023213761-A1 ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER UNIVERSITE DE GENEVE (CH) 2023-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115592-A1 ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885KDM4E 2545/4885HPGD 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.